Persistent use of psychotropic drugs in nursing home residents in Norway

Anne-Sofie Helvik, Jūratė Šaltytė Benth, Bei Wu, Knut Engedal and Geir Selbæk

Abstract

Background: The prevalence of psychotropic drug (PTD) use in NH residents is high, but few have explored prevalence and persistency in PTD in NH residents and factors associated with persistency. This at the same time as we know that risk of side events may be higher with long-term use in older adults. Thus, the aim of this study was to describe the prevalence and persistency in use of PTD and to explore factors associated with persistency in use of PTD at two consecutive time points in nursing home (NH) residents.

Methods: We included 1163 NH residents in a 72-month longitudinal study with five assessments. Use of PTD, neuropsychiatric symptoms (NPS), severity of dementia and physical health were assessed each time.

Results: The prevalence over time and persistent use of antipsychotic drugs, antidepressants, anxiolytics and sedatives at two consecutive time points were high in residents with and without dementia. There was an association between greater NPS at the first time point, and persistent use of these drugs, but changes in NPS between time points, did not explain such use. A longer NH stay increased the odds for persistent use of antipsychotics.

Conclusion: Psychotropic drugs are frequently used as a long-term treatment among NH residents and are associated with severity of neuropsychiatric symptoms, but not with severity of dementia. Closer attention should be paid to follow-up of psychotropic drug treatment, and especially for long-term use of antipsychotics, since the duration of such treatment should be as short as possible.

Keywords: ATC, Dementia, Older adults, Geriatrics, Long-term-use, Neuropsychiatric symptoms, Old age

Background

The use of psychotropic drugs in European nursing homes (NH) is reported to be quite common. The prevalence of use of any psychotropic drug (PTD) varied between 42 and 80% in studies published from 2005 to 2013 [1–6] and varied between countries [7, 8]. Among NH residents with dementia or cognitive impairment, the prevalence of any PTD use is similar or even higher than among those with normal cognition (48–90%) [9–14] and also higher than in community living older adults with dementia [14]. In NHs in Scandinavia, the use of any PTD is also high (57–80%) [15–19], especially in studies that only include residents with dementia (68–85%) [12, 15, 17, 20, 21].

Over the years there has been an increase in use of PTD in NH [12, 18, 22–28] except for antipsychotic drugs, where a decrease has been observed in recent years [18, 27, 29, 30]. Thus, the prevalence of antipsychotic drug use in Scandinavian NH residents with dementia is among the lowest in Europe (pooled estimates 24%) [31]. Antidepressants are the most commonly used PTD in Norwegian NH residents [16, 18, 22].

Antipsychotic drugs are often used to treat neuropsychiatric symptoms, such as aggression, agitation or psychotic symptoms in NH residents with dementia, although non-pharmacological interventions should be the first choice of treatment for these symptoms [32, 33]. However, in demanding clinical situations, antipsychotic drugs may be unavoidable, but there is no evidence that
long-term use of antipsychotic drugs in the management of neuropsychiatric symptoms is effective [33]. Older NH residents with dementia can be withdrawn from long-term antipsychotics without detrimental effects on their behavior, but caution is required in residents with severe neuropsychiatric symptoms [34]. Furthermore, the duration of antipsychotic drug treatment should be as short as possible, because of the high risk of side effects [32], such as more rapid progression of dementia [9] or cognitive decline [35], higher risk of cerebrovascular events [36] and increased risk of falling [37]. Use of antipsychotic drugs is also associated with increased mortality risk [38]. While the side effects of antipsychotics have received the most attention, studies show that there are serious short- and long-term side effects such as falls and fall-related fractures associated with use of antidepressants and with use of benzodiazepines [37]. The efficacy of antidepressants on depression in persons with dementia was not confirmed in a meta-analysis summarizing many randomized control trials [39]. A recent study of discontinuation of antidepressants in NH residents with dementia and neuropsychiatric symptoms in Norway found that most residents (85%) tolerated discontinuation [40]. However, when antidepressants are discontinued in residents with dementia they should be monitored carefully to identify those with worsening depressive symptoms [40]. Authors who studied retrospectively discontinuation of long-term use of benzodiazepines in older adults with and without dementia in care institutions found limited evidence of adverse outcomes due to discontinuation of benzodiazepines, but close attention should be paid to the possibility of emergent agitation and in patients with anxiety caution should be practiced [41]. Discontinuation of long-term use of Benzodiazepines in older adults without dementia has been found to increase handgrip strength, balance and cognitive function [42–44].

Of the approximately 75 studies on PTD in NH facilities published after 2004, only a small fraction have examined use of PTD in a longitudinal design [21, 45–54]. About half of the longitudinal studies have studied the prevalence of different types of PTD over time or persistent use at two time points [21, 45–48, 50, 52], but very few have studied factors associated with the persistent use of PTD, such as antipsychotic drugs [46, 52], antidepressants, anxiolytics or sedatives. However, as the risk of side events may be higher with long-term use [32, 33] and is decreased after discontinuation of PTD in older adults [34, 55] it is of vital importance to study the persistent use of PTD and its associated factors.

The aim of this study was to describe the prevalence and persistence of PTD use and to explore factors associated with the persistence in use of PTD at two consecutive time points in a Norwegian sample of NH residents.

Method
Design
This was a 72-month longitudinal study with five assessments. Baseline assessment (A1) took place between November 2004 and January 2005 [56]. The follow-up assessments took place after 12, 31 and 52 and 72 months (A2–A5).

Setting and participants
In total, Norway has 40,000 NH places (beds) [57] for a population of about five million, with about 14% (700,000) of those aged 65 years or older [58]. The jurisdiction for public health care services lies with local municipalities, and local authorities offer social services (such as housing and home services), in-home nursing and institutional care (mainly in NHs), and provide both long- and short-term care and rehabilitation.

This study recruited participants from 26 NHs in 18 municipalities. The selection of small, medium, and large municipalities was made to obtain a wide variety of NH-settings in the sample. NH residents with a stay of at least 14 days were eligible for inclusion, no other inclusion or exclusion criteria were used [56]. In all, 1165 residents were eligible for inclusion and only two declined to participate.

Measures
Psychotropic drugs were grouped according to the Anatomical Therapeutic Chemical (ATC) Classification System into the following groups: antipsychotics (N05A except lithium), antidepressants (N06A), anxiolytics (N05B), hypnotics/sedatives (N05C), and anti-dementia medication (N06D) (yes versus no) [59]. Combination drugs outside ATC N05B and N05C were not included. The information was collected from the medical record of each resident [56].

Dementia and severity of dementia was assessed using the Clinical Dementia Rating (CDR) scale, covering six domains (memory; orientation; judgment and problem solving; community affairs; home and hobbies; and personal care) with five response categories (0, 0.5, 1, 2, 3) [60, 61]. The total score was calculated using an algorithm that gives priority to memory [60]. Residents with a total score of one or higher were regarded as having dementia. The cut-off CDR ≥1 in defining dementia has been found adequate in previous Norwegian and international studies [62–64]. The categorical scores indicate the severity of dementia: a CDR score of 1 represents mild dementia, a CDR score of 2 represents moderate dementia, and a CDR score of 3 represents severe dementia. The sum-score of the six domains (sum of
boxes), ranging from zero to 18, can also be used to measure the severity of dementia, as the categorical and continuous scores correlate highly ≥ 0.9 [65, 66]. The Spearman correlation between the categorical CDR score and the CDR sum of boxes score in the present study was 0.93. Due to a wider range of values, the CDR sum of boxes offers important advantages when analyzing the data [66].

We used the CDR score (CDR ≥ 1) as an indication of dementia, as it was not possible to perform a standardized dementia work-up for all residents because many were too frail or mentally impaired to take part in examinations such as CT or MRI. A large number of residents with a CDR score of 3 could not be tested with any dementia tests such as the Mini Mental Status Examination [67] or the Clock Drawing Test [68].

Physical health was assessed using the General Medical Health Rating (GMHR) scale [69]. This is a one-item global rating scale with four categories: good, fairly good, poor, and very poor. The rating was based on all available information on physical health and use of drugs. The scale has been used in large studies including older people with and without dementia [70] and has been translated and used in several studies [71, 72].

The Personal Activities of Daily Living (P-ADL) score was assessed with the Physical Self-Maintenance Scale (PSMS), including six items, with a total score ranging from 6 to 30 [73]. High scores indicate a lower level of functioning.

Neuropsychiatric symptoms (NPS) were assessed using the Neuropsychiatric Inventory Nursing Home version (NPI-NH) [74, 75]. The 10-item inventory covers the following symptoms: delusion, hallucination, euphoria, agitation/aggression, disinhibition, irritability/lability, depression/dysphoria, anxiety, apathy/indifference, and aberrant motor behavior (no/yes). For each symptom, severity (score 1–3) multiplied by frequency (score 1–4) provides a score from zero to 12. Based on a previous principal component analysis, psychosis (delusions, hallucination), agitation (agitation/aggression, disinhibition, irritability), and affective (depression, anxiety) sub-syndrome scores were formed by summing the score of the included items [76–79]. The apathy/indifference was analyzed as a single symptom.

Demographic information such as age, gender, marital status, and length of stay in the NH at the time of inclusion was collected from medical records. The type of unit was also recorded from among the following options: regular units (RU), special care unit for people with dementia (SCU), rehabilitation unit (REU), and other units (OU), mainly psychogeriatric wards. The length of stay in a NH before study inclusion was measured in days.

**Procedure**

Nurses with extensive clinical experience collected the data. Prior to data collection, all assessors participated in a 2-day course on how to apply the standardized questionnaires. A 1-day training program was carried out prior to each follow-up assessment. The project leader (GS) was available for consultation throughout the data collection period. The nurses collected data from medical records and via a standardized interview with the residents’ primary caregivers, all of whom were registered nurses. All assessment scales used were standard translated Norwegian versions. A pilot study including 41 NH residents was carried out to test inter-rater reliability of CDR prior to the first data collection and the inter-rater reliability was very good. The kappa statistics for the global CDR score were 1 (between geriatric psychiatrist and registered nurse specialized in psychiatry) and 0.86 (between geriatric psychiatrist and registered nurse). More detailed information of the inter-rating reliability test has been published elsewhere [56].

Study information was given to the residents and their family members. The residents and their next of kin were informed that they could refuse to participate at any stage of the study. This procedure was recommended and approved by the Regional Ethics Committee in the south east of Norway, the Data Inspectorate and the Directorate for Health and Social Affairs in 2004 before data collection.

**Data analysis**

Sample characteristics at baseline were described as means and standard deviations (SD) or frequencies and percentages. Residents with CDR ≥ 1 and CDR < 1 were compared by Independent samples t-test for continuous and χ²-test for categorical variables. Prevalence and persistence of PTD use among those with and without dementia were compared by Z-test for proportions. The persistence in outcomes, use of antipsychotics, antidepressants, anxiolytics and sedatives were assessed with a logistic regression model for hierarchical data (SAS GLIMMIX procedure). Random effects for type of unit nested in a NH were included into the model. The dependent variable was current use of a specific type of PTD drug, while the independent variable was either use of the same drug at the previous time point (lag 1), two time points previously (lag 2) or three time points previously (lag 3). All models were adjusted for a number of relevant covariates measured at the same time point as the independent variable. A similar model was estimated to assess variables associated to persistent use of drugs, where the outcome was defined as 1 in the case of use of drugs at two adjacent time points and 0 otherwise. In addition, exploratory analyses assessing association between change in NPI sub-syndromes and persistent use of PTDs were done.
of drugs were performed. All multivariate models were reduced using Akaike's Information Criteria, where a lower value means a better model. The results were tabulated as odds ratios (ORs) with corresponding 95% confidence intervals (CI) and presented graphically.

All analyses were performed in SPSS version 22 and SAS v9.3. P-values below 0.05 were considered statically significant. All tests were two-sided.

Results

Sample characteristics

At baseline, the mean (SD) age of the residents was 84.4 (7.8) years and 846 (72.7%) of them were women (Table 1). The mean (SD) baseline CDR sum of boxes was 11.2 (5.3) and 932 (80.1%) residents had CDR ≥ 1 indicating dementia. The mean length of stay at baseline was 938.3 (1013.1) days and the mean (SD) number of prescribed drugs taken regularly was 6.0 (3.1). Of the 1163 residents at baseline, 98 (8.4%) were still alive and available at the fifth follow-up (see Fig. 1). Mean (SD) time of follow-up was 829.5 (690.0) days.

Prevalence of psychotropic drugs over time

The prevalence of PTD use at baseline and each of the follow-up time points are presented in Table 2. Antidepressants were most frequently used (38.3% at baseline, 32.7% at last follow-up); while anti-dementia drugs were least frequently used (11.3% at baseline, 0% at last follow-up). The prevalence of use of any PTD was high throughout the period; at baseline the prevalence was 72.9%, but had fallen to 63.3% at the last follow-up.

At baseline, the use of any PTD occurred more frequently in residents with dementia, while at the last follow-up any PTD was more often used in residents without dementia. Atypical antipsychotics were used more frequently in residents with dementia at A1–A3, whereas residents without dementia used anxiolytics more frequently at A2 and A3 and sedatives more frequently at A1–A4, respectively.

Persistent use of psychotropic drugs

The proportion of PTD use at two consecutive time points was high (>50%) throughout the period for all types of PTD, except for use of anti-dementia drugs (Table 2). Persistent use of anxiolytics at two consecutive time points was higher for residents without dementia than those with dementia. Among those who completed all assessments (n = 98), 10.4% used antipsychotic drugs, 19.8% used antidepressants, 11.5% used anxiolytics and 9.4% used sedatives at all assessments. Unadjusted and

| Table 1 Sample characteristics at baseline |
|------------------------------------------|
| A1 | CDR ≥ 1 | CDR < 1 | P-values* |
|-----------------|-------------|-----------|-----------|
| **Socio-demographics** | | | |
| Age Mean (SD) | 84.4 (7.8) | 84.5 (7.5) | 83.8 (9.0) | 0.223 |
| Females N (%) | 846 (72.7) | 686 (73.6) | 156 (68.7) | 0.139 |
| Education < 10 years N (%) | 847 (74.8) | 673 (74.1) | 170 (76.9) | 0.390 |
| Married N (%) | 221 (19.0) | 185 (19.8) | 36 (15.9) | 0.178 |
| **Health condition** | | | |
| GMHR | | | |
| Good N (%) | 194 (17.2) | 142 (15.7) | 52 (23.4) | <0.001 |
| Fairly good N (%) | 386 (34.1) | 291 (32.2) | 94 (42.3) | |
| Poor N (%) | 378 (33.4) | 322 (35.6) | 53 (23.9) | |
| Very Poor N (%) | 173 (15.3) | 150 (16.6) | 23 (10.4) | |
| PSMS score Mean (SD) | 18.1 (5.4) | 18.8 (5.3) | 15.4 (4.8) | <0.001 |
| NPI Agitation sub-syndrome Mean (SD) | 5.8 (8.0) | 6.5 (8.2) | 2.9 (6.1) | <0.001 |
| NPI Psychosis sub-syndrome Mean (SD) | 2.8 (5.1) | 3.2 (5.3) | 1.3 (3.8) | <0.001 |
| NPI Affective sub-syndrome Mean (SD) | 3.5 (5.3) | 3.7 (5.4) | 2.9 (4.9) | 0.041 |
| NPI Apathy Mean (SD) | 2.2 (3.7) | 2.4 (3.8) | 1.1 (2.9) | <0.001 |
| No of drugs Mean (SD) | 6.0 (3.1) | 5.8 (3.0) | 6.9 (3.3) | <0.001 |
| Days in NH Mean (SD) | 938.3 (1013.0) | 928.9 (910.1) | 975.5 (1359.3) | 0.534 |

CDR Clinical Dementia Rating scale
GMHR General Medical Health rating
PSMS Physical Self-Maintenance Scale
NPI Neuropsychiatric Inventory
NH Nursing home

*Calculated by using t-test for Independent samples for continuous or χ²-test for categorical variables
adjusted odds for use of PTD at one time point, given use of the same type of PTD at an earlier time point was estimated for all types of PTD except for anti-dementia drug use (Table 3 and Fig. 2). Both in unadjusted and adjusted analyses, the odds for persistent use of antipsychotics, antidepressants, anxiolytics and sedatives were high. The odds for persistent use of these PTD were highest when compared with use at the closest earlier assessment time point (Lag 1) and fell successively when the distance between the assessment time points increased (Lags 2 and 3), with one exception for antipsychotics where the odds slightly increased when there were three time points between assessments (Lag 3) compared to two time points (Lag 2). All results were highly significant ($p < 0.001$).

Factors associated with use of psychotropic drugs at two consecutive time points

The adjusted risk for persistent use of antipsychotics at two consecutive time points was elevated when residents had higher psychosis sub-syndrome score or were younger, were male or had a longer NH stay at baseline (Table 4). The adjusted risk for persistent use of antidepressants was elevated when residents had higher P-ADL functioning (lower PSMS score) or higher affective sub-syndrome score. The adjusted risk for persistent use of anxiolytics was elevated when residents had higher P-ADL functioning (lower PSMS score) or higher affective sub-syndrome score or stayed in a larger NH (Table 5). The adjusted risk for persistent use of sedatives was elevated when residents had better cognitive functioning (lower CDR sum of boxes) or higher affective sub-syndrome score or lower apathy symptom score.

In a subsequent analysis where sub-syndrome scores of NPS at the first time point were replaced by change in sub-syndrome score between the two assessments, we found no association between change in the sub-syndrome scores of NPS and persistent use of antipsychotic drugs, antidepressants, anxiolytics or sedatives.

**Discussion**

In this Norwegian NH study, the prevalence and persistent use of PTD at two consecutive time points was high, both for residents with and without dementia, except for use of an anti-dementia drug. Close to three-quarters of the dementia and two-thirds of non-dementia residents used PTD at baseline of the data collection. Persistent use of anxiolytics was more common in residents without dementia. The persistent use decreased gradually when the distance between the assessment time points increased (Lags 2 and 3), with the exception of the use of antipsychotics drugs. More severe NPS were associated with persistent use of antipsychotics drugs, antidepressants, anxiolytics and sedatives at the next time point, but change in NPS between the time points was not associated with persistent use of PTD. Better P-ADL...
functioning (lower PSMS score) was associated with persistent use of antidepressants and anxiolytics. Furthermore, less severe dementia was associated with persistent use of sedatives. Of the organizational variables included in the analysis, we found that a longer stay in NH increased the odds for persistent use of antipsychotics at two consecutive time points and staying in a larger-sized NH increased the odds for persistent use of anxiolytics.

Use of antipsychotics

The study found that the prevalence of atypical antipsychotics was higher in residents with dementia than in residents without, but only for the first three time points. Use of conventional antipsychotics did not differ between residents with or without dementia at any time point. The persistence in use of both atypical and conventional antipsychotics at two consecutive time points was high (>50%) during the entire follow-up period of 72 months for both groups of residents. A small 6-month follow-up study of newly arrived NH residents in Australia has previously reported the persistence of antipsychotics to be equally high [49]. Given the strong evidence on the increased mortality risk associated with use of conventional antipsychotics in people with dementia it is rather surprising to see that they are still used to that extent. These findings are alarming, since the duration of such treatment should be as short as possible [32]. In the present adjusted logistic regression analysis for persistent use of antipsychotic drugs at two consecutive time points, higher severity of psychosis increased the risk for persistent use of antipsychotics. However, it is surprising that in the exploratory analysis, a change in NPS was not associated with persistent use of antipsychotics. Clinical recommendations have highlighted the need for clinicians to monitor NPS closely and consider discontinuing treatment with antipsychotics when an obvious treatment effect does not occur or the residents have side effects due to the treatment [32]. It could be that people receiving PTD had more severe symptoms prior to drug initiation. Also, it could be that antipsychotics were described as unspecific

### Table 2 Prevalence and persistence of PTD use according to the presence of dementia at each assessment (%)

|                      | A1       | A2       | A3       | A4       | A5       |
|----------------------|----------|----------|----------|----------|----------|
|                      | All (n = 1163) | D/nD (n = 932/227) | All (n = 789) | D/nD (n = 628/159) | All (n = 395) | D/nD (n = 300/94) | All (n = 209) | D/nD (n = 160/48) | All (n = 98) | D/nD (n = 75/22) |
| Antipsychotics (AP)  | 24.1     | 26.0/15.9*** | 25.2     | 26.4/20.8 | 20.5     | 22.0/16.0 | 20.6     | 22.5/14.6 | 20.4     | 20.0/22.7  |
| Trad. AP             | 11.3     | 11.5/11.0 | 12.2     | 11.6/14.5 | 9.4      | 9.0/10.6  | 8.6      | 9.4/6.3   | 12.2     | 12.0/13.6  |
| Atypical AP          | 13.2     | 14.9/5.7*** | 13.8     | 15.6/6.9*** | 11.9     | 13.7/6.4** | 12.6     | 13.1/8.3  | 8.2      | 8.0/9.1    |
| Antidepressants      | 38.3     | 39.1/34.8 | 37.3     | 37.9/34.0 | 36.7     | 35.3/40.4 | 35.4     | 33.1/41.7 | 32.7     | 29.3/40.9  |
| Anxiolytics          | 24.2     | 23.8/26.4 | 24.2     | 22.9/29.6* | 25.1     | 21.3/37.2*** | 28.7     | 26.9/35.4 | 22.4     | 21.3/27.3  |
| Sedatives            | 29.0     | 26.4/39.6*** | 26.6     | 23.4/38.4*** | 24.1     | 21.0/33.0* | 23.9     | 19.4/37.5** | 23.5     | 20.0/31.8  |
| Antidementia drug    | 11.3     | 13.5/2.2*** | 9.8      | 11.8/1.9*** | 5.3      | 6.3/2.1*  | 2.9      | 3.1/2.1   | 0        | 0/0        |
| Any PTD              | 72.9     | 74.5/66.5* | 71.4     | 71.5/70.4 | 70.4     | 67.7/78.7* | 69.4     | 66.9/77.1 | 63.3     | 57.3/81.8** |

### Persistence at two consecutive time points in percentages

|                      | A1–A2 | A2–A3 | A3–A4 | A4–A5 |
|----------------------|-------|-------|-------|-------|
|                      | All D/nD | All | All D/nD | All | All D/nD |
| Antipsychotics (AP)  | 76.7   | 75.2/88.9* | 64.9 | 67.6/55.0 | 69.6 | 67.5/83.3 | 70.0 | 68.8/75.0 |
| Trad. AP             | 73.6   | 70.8/84.2 | 61.4 | 63.3/57.1 | 73.7 | 73.3/75.0 | 80.0 | 75.0/100 |
| Atypical AP          | 74.5   | 74.7/80.0 | 61.5 | 63.0/50.0 | 62.1 | 59.3/100*** | 60.0 | 62.5/50.0 |
| Antidepressants      | 80.4   | 79.8/82.8 | 76.5 | 73.1/87.9* | 72.2 | 66.1/89.5** | 75.7 | 76.9/70.0 |
| Anxiolytics          | 76.9   | 73.6/89.5** | 69.2 | 62.7/84.4** | 86.8 | 82.1/100** | 66.7 | 66.7/66.7 |
| Sedatives            | 70.9   | 65.8/82.8** | 64.8 | 69.1/55.6 | 69.6 | 64.9/77.8 | 68.0 | 58.8/85.7 |
| Antidementia drug    | 66.0   | 65.3/100*** | 38.1 | 36.6/100*** | 27.3 | 27.3/0    | 0    | 0/0        |
| Any PTD              | 89.8   | 88.7/94.3* | 85.3 | 82.4/94.2** | 89.3 | 86.6/97.3** | 78.4 | 75.5/85.0 |

**Table 2** Prevalence and persistence of PTD use according to the presence of dementia at each assessment (%)

A1–A5: Assessment 1–5  
D Dementia CDR ≥ 1; nD No dementia CDR < 1  
CDR ratings were missing for 4 people at A1, 2 people at A2 and 2 people at A3  
CDR Clinical Dementia Rating scale  
Trad Conventional  
PTD Psychotropic drugs  
* p < 0.05, ** p ≤ 0.01; *** p ≤ 0.001 (Z-test for proportions used)
sedatives. Very few studies have examined variables associated with persistent use of antipsychotics in NH residents [46, 52], but none of these studies have explicitly explored the importance of NPS in the persistent use of antipsychotic drugs. However, cross-sectional studies have explored the association between NPS and use of antipsychotic drugs and found that higher total symptom load [80] and more severe psychosis sub-syndromes symptoms were associated with use of antipsychotics [11, 14, 81, 82].

In the adjusted logistic regression analysis of use of antipsychotics, younger age and male gender increased the risk for persistent use of antipsychotics. In contrast, a small Swedish 6-month follow-up study in NH residents with dementia did not find age, gender or other personal characteristics of the residents such as P-ADL or cognitive functioning important for persistent use of antipsychotics [52]. Our finding may partly be explained by age and gender-based expressions of behavioral symptoms [80] not captured by the NPS. Male and younger residents may be experienced as more threatening in their verbal or physical expressions and are physically stronger compared to women and older residents, and for this reason may be put on antipsychotic drugs. In line with our results, cross-sectional studies of use of antipsychotics in NH residents have found that younger residents [4, 8, 15, 22, 80, 82, 83] and male residents [5, 80, 84] are more likely to receive antipsychotics.

Persistent use of antipsychotics has been reported to be more frequent in regular care units than in SCU [46]. In the present study we did not find an association between the type of care unit and persistent use of antipsychotics. In Norway, SCUs have residents with more severe NPS than other units, which could explain our result [30]. However, we found that residents with a longer stay in NH at baseline had an increased likelihood of being persistent users of antipsychotics. We do not have a firm explanation for this, but it may be that newly arrived NH residents receive more attention from the staff.

Table 3 Odds ratios for use of each category of psychotropic drugs at one time point given use of the same category of the psychotropic drug at an earlier time point (the distance between time points is called lag), unadjusted and adjusted analyses where relevant covariates adjusted for were measured at the same earlier time

| Variables | Unadjusted | | Adjusted | |
| --- | --- | --- | --- | --- |
| | OR (95% CI) | P-value | OR (95% CI) | P-value |
| Lag 1, N = 1406 observations | | | | |
| Antipsychotics | 30.7 (21.8; 43.1) | <0.001 | 28.8 (20.3; 40.8) | <0.001 |
| Antidepressants | 32.6 (23.8; 44.8) | <0.001 | 34.1 (24.6; 47.4) | <0.001 |
| Anxiolytics | 33.1 (23.7; 46.2) | <0.001 | 32.2 (23.1; 45.0) | <0.001 |
| Sedatives | 22.6 (15.6; 30.8) | <0.001 | 23.1 (16.8; 31.7) | <0.001 |
| Lag 2, N = 654 observations | | | | |
| Antipsychotics | 13.3 (8.3; 21.4) | <0.001 | 13.5 (8.1; 22.3) | <0.001 |
| Antidepressants | 15.5 (9.9; 24.2) | <0.001 | 16.0 (10.2; 25.3) | <0.001 |
| Anxiolytics | 21.4 (12.8; 35.7) | <0.001 | 23.4 (13.9; 39.6) | <0.001 |
| Sedatives | 9.3 (5.9; 14.4) | <0.001 | 9.4 (5.9; 14.8) | <0.001 |
| Lag 3, N = 288 observations | | | | |
| Antipsychotics | 16.5 (7.5; 36.3) | <0.001 | 17.9 (7.5; 42.4) | <0.001 |
| Antidepressants | 10.0 (4.9; 20.4) | <0.001 | 12.6 (5.8; 27.2) | <0.001 |
| Anxiolytics | 14.4 (6.5; 32.1) | <0.001 | 14.3 (7.0; 29.2) | <0.001 |
| Sedatives | 7.0 (3.6; 13.9) | <0.001 | 6.4 (3.2; 12.6) | <0.001 |

Lag 1: two consecutive assessment time points
Lag 2: one time point between selected time points
Lag 3: two time points between selected time points
aAdjusted for: PSMS score, NPI Agitation sub-syndrome, NPI Psychosis sub-syndrome, NPI Affective sub-syndrome, NH size age and duration in NH
bAdjusted for: PSMS score, NPI- Affective sub-syndrome, NPI Apathy and duration in NH
cAdjusted for CDR sum of boxes, NPI- Affective sub-syndrome and level of education
dAdjusted for PSMS score, NPI Apathy and duration in NH
eAdjusted for PSMS score, NPI Psychosis sub-syndrome, NPI Apathy, Type of nursing home and age
fAdjusted for: CDR sum of boxes, PSMS score and NPI- Affective sub-syndrome
gAdjusted for CDR sum of boxes, PSMS score and level of education
hAdjusted for CDR sum of boxes, PSMS score and age
iAdjusted for PSMS score and age
jAdjusted for: CDR sum of boxes, NPI- Affective sub-syndrome and NPI Apathy
kAdjusted for NPI Agitation sub-syndrome, NPI Psychosis sub-syndrome, NPI Affective sub-syndrome, NPI Apathy, level of education and Type of nursing home unit
lAdjusted for CDR sum of boxes, NPI Psychosis sub-syndrome and Nursing home size
or respond better to care that is intended to reduce stress, strain and symptoms related to dementia.

**Use of antidepressants**

We found, in line with other studies, that antidepressants were the most frequently used PTD in NH residents [48, 49] and that the frequency did not differ between residents with or without dementia [85]. The persistence of use of antidepressants was also high [49]. As we could expect, those with more severe affective symptoms had higher odds for persistent use of antidepressants. This result is in line with cross-sectional studies of associations for use of antidepressants [11, 15, 81]. Even so, the efficacy of antidepressants in treating depression in persons with dementia is uncertain. The high prevalence and persistence of antidepressants use may indicate that these drugs also are used for the treatment of agitation. Better performance in P-ADL was more likely to be associated with persistent antidepressant users. We do not have a firm explanation for this, but it may be that those with better P-ADL also have a better ability to express their emotional state.

**Use of anxiolytics, sedatives and anti-dementia drugs**

The prevalence of anxiolytics in the NH residents varied between 20 and 40%, and was significantly higher in residents without dementia, while the persistent use of anxiolytics in adjusted analysis was not explained by the severity of dementia. As for antidepressants, persistent use of anxiolytics was explained by more severe affective symptoms and better P-ADL functioning, but not by change in affective sub-syndrome symptoms between time points. The size of the NH was associated with persistent use of anxiolytics. We speculate that staff distress [81], registered nursing hours per resident [86] and other organizational factors [5] that we have not measured may be related to NH size, quality of care and use or persistent use of anxiolytics.

Use of sedatives was higher among residents without dementia than residents with dementia and varied between 19 and 26% in residents with dementia and between 32 and 40% in residents without dementia. A possible explanation may be that residents without dementia are more vulnerable to disturbances in the NH environment and at the same time may be more able to ask for sedatives than residents with dementia.

The prevalence of anti-dementia drugs use was at baseline 11.3% for all residents and as expected the prevalence of such use declined at each of the follow-ups and at the fifth assessment no one used anti-dementia drugs. At the four first assessment time points between 1.9 to 2.2% of residents with CDR less than 1 were prescribed anti-dementia drugs. This may indicate that the NH physicians have prescribed the anti-dementia drugs without having a dementia diagnosis (P70), but the physicians may have used the diagnosis cognitive problems (P20) as an indication for prescribing the drug. This is quite common in Norway. However, in a recent Norwegian study it was found that a substantial number of persons who purchased anti-dementia drugs

---

**Fig. 2 Illustration of OR for use of each category of psychotropic drugs at one time point given use of the same category of psychotropic drug at an earlier time point by distance (Lag) between the time points, unadjusted and adjusted.**

- **a** Antipsychotics
- **b** Antidepressants
- **c** Anxiolytics
- **d** Sedatives
had no diagnosis of dementia or cognitive problems registered in the primary health care service system [87].

**Strength and limitations**

The study has significant strengths. Firstly, all nurses participating in the data collection participated in a 2-day educational course to ensure that they had adequate knowledge prior to collecting data for this study and participated in a 1-day educational course before the follow-up data collections. This ensured high data quality. Secondly, a large sample size allowed us to adjust for many potentially important variables, such as health and demographic factors. Furthermore, this study benefits from the inclusion of NHs located in a large part of the country. However, we cannot guarantee that the sample is representative for Norwegian NH residents since inclusion was not based on random selection from all NHs in Norway.

The study has some limitations. Firstly, the data from the present study is quite old since data collection started in 2004, and thus, may not represent medication use patterns in Norwegian NHs of today. Secondly, a high drop-out rate mainly due to death might have introduced some bias into the results. However, this methodological problem is inherent to most longitudinal NH studies. Also, we used linear mixed models that include all available data (data from drop-outs as well) in the analysis. Due to the low number of participants at the end of the follow-up period, the analysis of persistence was limited to three lags only. Thirdly, the time intervals between the assessments varied somewhat among participants. However, this affects the results only minimally, since the time intervals between assessments were quite

### Table 4

| Variables Assessed at previous time point | Antipsychotics | Antidepressants |
|------------------------------------------|----------------|-----------------|
|                                          | Unadjusted     | Adjusted        | Unadjusted     | Adjusted        |
|                                          | OR (95% CI)    | P-value         | OR (95% CI)    | P-value         |
| CDR sum of boxes                        | 1.04 (1.002; 1.07) | 0.036           | 0.97 (0.95; 0.995) | 0.020           |
| GMHR Good                                | 1.25 (0.66; 2.37) | 0.498           | 0.98 (0.59; 1.63) | 0.934           | 0.63 (0.35; 1.12) | 0.111 |
| Fairly good                              | 1.11 (0.63; 1.98) | 0.715           | 1.29 (0.82; 2.02) | 0.273           | 0.92 (0.56; 1.51) | 0.745 |
| Poor                                     | 1.53 (0.86; 2.72) | 0.151           | 1.62 (1.03; 2.56) | 0.038           | 1.34 (0.83; 2.16) | 0.229 |
| Very Poor                                | 1              | -              | 1              | -              | 1              | -              |
| PSMS score                               | 1.03 (0.997; 1.06) | 0.073           | 0.96 (0.94; 0.98) | 0.001           | 0.94 (0.91; 0.97) | 0.001 |
| NPI Agitation sub-syndrome               | 1.05 (1.03; 1.07) | <0.001          | 1.02 (0.997; 1.04) | 0.093           | 0.997 (0.98; 1.01) | 0.714 |
| NPI Psychosis sub-syndrome               | 1.09 (1.06; 1.12) | <0.001          | 1.06 (1.03; 1.10) | <0.001          | 1.00 (0.98; 1.03) | 0.915 |
| NPI Affective sub-syndrome               | 1.06 (1.03; 1.09) | <0.001          | 1.03 (0.999; 1.07) | 0.060           | 1.08 (1.05; 1.10) | <0.001 |
| NPI Apathy                               | 1.07 (1.03; 1.12) | <0.001          | 0.99 (0.96; 1.03) | 0.732           |

| Assessed at baseline                     | Antipsychotics | Antidepressants |
|------------------------------------------|----------------|-----------------|
|                                          | Unadjusted     | Adjusted        | Unadjusted     | Adjusted        |
|                                          | OR (95% CI)    | P-value         | OR (95% CI)    | P-value         |
| Age                                      | 0.95 (0.93; 0.97) | <0.001          | 0.95 (0.93; 0.97) | <0.001          | 0.99 (0.98; 1.01) | 0.317 |
| Females                                  | 0.56 (0.40; 0.80) | 0.001           | 0.64 (0.44; 0.93) | 0.019           | 1.38 (1.02; 1.87) | 0.035 |
| Education (<=10 years)                   | 0.97 (0.68; 1.39) | 0.865           | 0.88 (0.66; 1.17) | 0.385           |
| Duration in NH (LN)                     | 1.21 (1.06; 1.40) | 0.007           | 1.21 (1.05; 1.40) | 0.011           | 0.98 (0.88; 1.09) | 0.654 |
| Nursing home size                       | 0.998 (0.993; 1.003) | 0.382           | 1.00 (0.998; 1.01) | 0.347           |
| Type of nursing home unit               | 1              | -              | 1              | -              |
| RU                                       | 1              | -              | 1              | -              |
| REU                                      | 0.57 (0.10; 3.41) | 0.539           | 1.03 (0.30; 3.51) | 0.959           |
| SCU                                      | 1.24 (0.78; 1.97) | 0.367           | 0.80 (0.55; 1.17) | 0.248           |
| OU                                       | 3.25 (0.63; 16.81) | 0.160           | 1.13 (0.28; 4.61) | 0.865           |

**RU** Regular units
**REU** rehabilitation unit
**SCU** special care unit for people with dementia
**OU** other units

The relative importance of each covariate in the adjusted models is included with a number after the 95% CI; lowest number has highest importance.
long and not used in the models explicitly, only as lags. In the present study the time intervals between the assessments were 1 year or more and due to the study design, we do not know whether there were changes in PTD use between assessments.

Fourthly, there is a limitation on the accuracy of dementia diagnoses, since dementia and degree of dementia are based on the CDR rating of several assessors and the fact that a CDR assessment was used, and not a standardized dementia diagnosis, including neuropsychological tests. A large number of residents with a CDR score of 3 could not be tested with any dementia tests such as the Mini Mental Status Examination or the Clock Drawing Test. However, CDR is an accepted assessment tool and is commonly used in epidemiological NH studies to identify dementia and measure the severity of dementia [65, 88], and the agreement between CDR and a diagnostic assessment according to the ICD-10 is high [62].

**Conclusion**

Psychotropic drugs were frequently used as a long-term treatment among NH residents and were associated with severity of neuropsychiatric symptoms, but not with severity of dementia. The high prevalence and persistence of psychotropic drug use may indicate that the treatment is not in line with current treatment recommendation. It is important that clinicians monitor effects and side effects of PTD treatment closely and stop treatment when the risk is not balanced by considerable benefits to the NH resident.
Abbreviations
CDDR: Clinical Dementia Rating; CI: Confidence intervals; GMHR: General Medical Health Rating; NH: Nursing home; NPI: Neuropsychiatric Inventory; NPS: Neuropsychiatric symptoms; OR: Odds ratio; OU: Other units; P-ADL: Personal Activities of Daily Living; PSM: Physical Self-Maintenance Scale; PTD: Psychotropic drugs; REU: Rehabilitation unit; RU: Regular units; SCU: Special care unit for people with dementia; SD: Standard deviation

Acknowledgements
Not applicable.

Funding
Data collection was funded by unrestricted grants from the Eastern Norway Regional Health authorities.

Availability of data and material
The datasets analyzed during the current study are not publicly available due access limitations given by the Regional Ethics Committee in the south east of Norway, the Data Inspectorate and the Directorate for Health and Social Affairs in 2004.

Authors’ contributions
GS and KE designed the study. GS was responsible for the data collection and quality assurance of the study results. JSB analyzed the majority of the data for this manuscript, and ASH did some analysis and drafted the manuscript. All authors participated in interpreting the study results, editing the manuscript, as well as reading and approving the final manuscript.

Competing interest
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was recommended and approved by the Regional Ethics Committee in the south east of Norway, the Data Inspectorate and the Directorate for Health and Social Affairs in 2004 before data collection. Study information in written and oral form was given to the residents and in case of limited capacity to understand the information, to their closest family proxy. The responsible health worker at the nursing home decided whether the resident had capacity to understand the information. No explicit consent was required and the participants were included on an opt-out basis. Furthermore, the residents or their next of kin were informed that they could refuse to participate at any stage of the study. This procedure was approved by the Regional Ethics Committee in the south east of Norway and the Data Inspectorate and the Directorate for Health and Social Affairs.

Author details
1Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Postboks 8005 NO-7491 Trondheim, Norway. 2St Olavs University Hospital, Trondheim, Norway. 3Norwegian National Advisory Unit on Ageing and Health, Vestfold Health Trust, Tønsberg, Norway. 4Institute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway. 5HØKH, Research Centre, Akershus University Hospital, Lørenskog, Norway. 6Centre for Old Age Psychiatric Research, Innlandet Hospital Trust, Otterstad, Norway. 7Rory Meyers College of Nursing, New York University, New York, NC, USA. 8Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway.

Received: 4 November 2016 Accepted: 2 February 2017

Published online: 13 February 2017

References
1. Huber M, et al. Antipsychotic drugs predominate in pharmacotherapy of nursing home residents with dementia. Pharmacopsychiatry. 2012;45:182–8.

2. Hosia-Randell H, Pirkola K. Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging. 2005;22:793–800.

3. Gobert M, D’Hoore W. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. Int J Geriatr Psychiatry. 2005;20:712–21.

4. Azermal M, Elseviers M, Petrovic M, van Bortel L, Stichele Rv. Assessment of antipsychotic prescribing in Belgian nursing homes. Int Psychogeriatr. 2011;23:1240–8.

5. Petek Ster M, Cedolin Gurup E. Psychotropic medication use among elderly nursing home residents in Slovenia: cross-sectional study. Croat Med J. 2011;52:16–24.

6. Mann E, et al. Prevalence and associations of potentially inappropriate prescriptions in Austrian nursing home residents: secondary analysis of a cross-sectional study. Wien Klin Wochenschr. 2013;125:180–8.

7. Richter T, Mann E, Meyer G, Haastert B, Kopke S. Prevalence of psychotropic medication use among German and Austrian nursing home residents: a comparison of 3 cohorts. J Am Med Dir Assoc. 2012;13:187.e7–187.e13.

8. Feng Z, et al. Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. Int J Geriatr Psychiatry. 2009;24:1110–8.

9. Eggermont LH, de Vries K, Scherder EJ. Psychotropic medication use and cognition in institutionalized older adults with mild to moderate dementia. Int Psychogeriatr. 2009;21:941–8.

10. Zuidema SU, Derksen E, Verhey FR, Koopmans RT. Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. Int J Geriatr Psychiatry. 2007;22:632–8.

11. Nikj RM, Zuidema SU, Koopmans RT. Prevalence and correlates of psychotropic drug use in Dutch nursing home patients with dementia. Int Psychogeriatr. 2009;21:485–93.

12. Lovheim H, Sandman PO, Karlsson S, Gustafson Y. Changes between 1982 and 2000 in the prevalence of behavioral symptoms and psychotropic drug treatment among old people with cognitive impairment in geriatric care. Int Psychogeriatr. 2009;21:941–8.

13. Balalle C, Jayalath D, Shankar K, Ashaye K. Prevalence and management of behavioural and psychiatric symptoms on a continuing care unit for patients with dementia. Int J Psychiatry Med. 2010;40:425–38.

14. Int J Geriatr PsychiatryPsychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA. . 2016(Maust DT, Langa KM, Blow FC, Kales HC).

15. Gustafsson M, Sandman PO, Karlsson S, Gustafson Y, Lovheim H. Association between behavioral and psychological symptoms and psychotropic drug use among old people with cognitive impairment living in geriatric care settings. Int Psychogeriatr. 2013;25:1415–23.

16. Selbaek G, Kirkevold O, Engedal K. Psychiatric and behavioural symptoms and the use of psychotropic medication in Special Care Units and Regular Units in Norwegian nursing homes. Scand J Caring Sci. 2008;22:568–73.

17. Olsson J, et al. Quality of drug prescribing in elderly people in nursing homes and special care units for dementia: a cross-sectional computerized pharmacy register analysis. Clin Drug Invest. 2010;30:289–300.

18. Ruths S, et al. Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts. Int J Geriatr Psychiatry. 2013;28:868–76.

19. Nurminen J, Puustinen J, Kukola M, Kivela SL. The use of chemical restraints for older long-term hospital patients: a case report from Finland. J Elder Abuse Negl. 2009;21:89–104.

20. Bergh S, Engedal K, Roen I, Selbaek G. The course of neuropsychiatric symptoms in patients with dementia in Norwegian nursing homes. Int Psychogeriatr. 2011;23:1231–9.

21. Selbaek G, Kirkevold O, Engedal K. The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes—a 12-month follow-up study. Am J Geriatr Psychiatry. 2008;16:528–36.

22. Nygaard HA, Ruths S, Straand J, Naik M. Not less but different: psychotropic drug utilization trends in Norwegian nursing homes during a 12-year period. The Bergen District Nursing Home (BEDNURS) Study. Aging Clin Exp Res. 2004;16:277–82.

23. Connelly PJ, Law E, Angus S, Prentice N. Fifteen year comparison of antipsychotic use in people with dementia within hospital and nursing home settings: sequential cross-sectional study. Int J Geriatr Psychiatry. 2010;25:160–5.

24. Castle NG, Hanlon JT, Handler SM. Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006. Am J Geriatr Pharmacother. 2009;7:143–50.
25. Gaboda D, Lucas J, Siegel M, Kalay E, Crystal S. No longer undertreated? Depression diagnosis and antidepressant therapy in elderly long-stay nursing home residents, 1999 to 2007. J Am Geriatr Soc. 2011;59:673–80.

26. Hanlon JT, Handler SM, Castle NG. Antidepressant prescribing in US nursing homes between 1996 and 2006 and its relationship to staffing patterns and use of other psychotropic medications. J Am Med Dir Assoc. 2010;11:320–4.

27. Vasudev A, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004-2013. Am J Geriatr Psychiatry. 2015;23:1259–69.

28. Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, Shaffer T, Zhao L. Association of antidepressant use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry. 2009;17:41–77.

29. Alanen HM, Finne-Soveri H, Noro A, Leinonen E. Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. Int J Geriatr Psychiatry. 2006;21:288–95.

30. Helvik AS, et al. Severity of neuropsychiatric symptoms in nursing home residents. Dement Geriatr Cogn Dis Extra. 2016;6:S28–42.

31. Janus SJ, van Manen NG, Ljzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. Int Psychogeriatr. 2016;1–16.

32. Jeste DV, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology. 2008;33:957–70.

33. Sink KM, Holden KD, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293:569–608.

34. Dekerpaz T, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013. doi:10.1002/14651858.CD007726.pub2.

35. Hartikainen S, Lonnroos E, Louhivuori K. Medication as a risk factor for falls: critical systematic review. J Gerontol A Biol Sci Med Sci. 2007;62:1172–81.

36. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–43.

37. Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antipsychotic studies in people with depression and dementia. J Am Geriatr Soc. 2011;59:577–85.

38. Bergh S, Selbaek G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double-blind, randomised, parallel group, placebo-controlled trial. BMJ. 2013;344, e1566.

39. Yokoi Y, Misal M, Oh E, Bellantoni M, Rosenberg PB. Benzodiazepine withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. BMC Geriatr. 2014;14:121.

40. Parsons C, et al. Sedative load of medications prescribed for older people with dementia in care homes. BMC Geriatr. 2011;11:56.

41. Gustafsson M, Karlsson S, Lovheim H. Inappropriate long-term use of antipsychotic drugs is common among people with dementia living in specialized care units. BMC Pharmacol Toxicol. 2013;14:10.

42. van de Ven-Valkheeva J, Bor H, Wetzels RB, Koopmans RT, Zuidema SU. The impact of antipsychotics and neuropsychiatric symptoms on the quality of life of people with dementia living in nursing homes. Int J Geriatr Psychiatry. 2013;28:530–8.

43. Verbeek H, Zwikahlen SM, van Rossum E, Ambergen T, Kempen G, Hamers JP. Effects of small-scale, home-like facilities in dementia care on residents’ behavior, and use of physical restraints and psychotropic drugs: a quasi-experimental study. Int Psychogeriatr. 2014;26:657–68.

44. van der Cammen TJ, Rajkumar C, Onder G, Sterke CS, Petrovic M. Drug cessation in complex older adults: time for action. Age Ageing. 2014;43:20–5.

45. Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry. 2007;22:843–9.

46. Statsbysjettet 2013 Finansdepartementet, Editor. 2013, http://www.statsbysjettet.no/Statsbysjettet.no/Statsbysjettet-2013/Budsgjennomslag/ Bevigningspornal/FremKrnktspant/179/?parti=hpopp.

47. Ritzl M, Resnick B, Chipperdla R, Galvin J. Testing a family-centered intervention to promote functional and cognitive recovery in hospitalized older adults. J Am Geriatr Soc. 2014;62:398–407.

48. 2015 WCCDSM. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD Index, 2015. Oslo. 2015; 26.08.2015.

49. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–72.

50. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.

51. Engedal K, Haugen P. The prevalence of dementia in a sample of elderly Norwegians. Int J Geriatr Psychiatry. 1993;8:565–70.

52. Nygaard HA, Naik M, Ruths S. Mental impairment in nursing home residents. Tidsskr Nor Lægeforen. 2010;130:113–6.

53. Walte L, et al. Informant-based staging of dementia using the clinical dementia rating. Alzheimer Dis Assoc. 1999;13:34–7.

54. Mojurk M, Kirkevold M, Resviki V, Selbaek G, Engedal K. Variables associated to quality of life among nursing home patients with dementia. Aging Ment Health. 2014;18:1013–21.

55. O’Byant SE, et al. Staging dementia using clinical dementia rating scale sum of boxes scores: a Texas Alzheimer’s research consortium study. Arch Neurol. 2008;65:1091–5.

56. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.

57. Shullman K. Clock-drawing: is it the ideal cognitive screening test? Int J Geriatr Psychiatry. 2000;15:548–61.

58. Lyketsos CG, et al. The General Medical Health Rating: a bedside global rating of medical comorbidity in patients with dementia. J Am Geriatr Soc. 1999;47:847–91.

59. Lyketsos C, et al. Population-based study of medical comorbidity in early dementia and “cognitive impairment, no dementia (CIND)”: association with functional and cognitive impairment: the cache county study. Am J Geriatr Psychiatry. 2004;13:566–64.

60. Helvik AS, et al. Health-related quality of life in older depressed psychogeriatric patients: one year follow-up. BMC Geriatr. 2016;16:131.

61. Wergeland JN, Selbaek G, Bergh S, Soederhamn U, Kirkevold O. Predictors for nursing home admission and death among community-dwelling people 70 years and older who receive domiciliary care. Dement Geriatr Cogn Dis Extra. 2015;5:320–9.

62. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.

63. Cummings JL, the neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:510–6.

64. Selbaek G, Kirkevold O, Sommer OH, Engedal K. The reliability and validity of the Norwegian version of the Neuropsychiatric Inventory, nursing home version (NPI-NH). Int Psychogeriatr. 2008;20:375–82.
76. Colombo M, Vitali S, Cairati M, Vaccaro R, Andreoni G, Guaita A. Behavioral and psychotic symptoms of dementia (BPSD) improvements in a special care unit: a factor analysis. Arch Gerontol Geriatr. 2007;44 Suppl 1:113–20.

77. Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Neuropsychiatric symptoms in nursing home patients: factor structure invariance of the Dutch nursing home version of the neuropsychiatric inventory in different stages of dementia. Dement Geriatr Cogn Disord. 2007;24:169–76.

78. Selbaek G, Engedal K, Bentham JS, Bergh S. The course of neuropsychiatric symptoms in nursing-home patients with dementia over a 53-month follow-up period. Int Psychogeriatr. 2013;1–11.

79. Syllaas H, Selbaek G, Bergland A. Do behavioral disturbances predict falls among nursing home residents? Aging Clin Exp Res. 2012;24:251–6.

80. Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother. 2008;6:187–97.

81. Zuidema SU, de Jonghe JF, Verhey FR, Koopmans RT. Psychotropic drug prescription in nursing home patients with dementia: influence of environmental correlates and staff distress on physicians’ prescription behavior. Int Psychogeriatr. 2011;23:1632–9.

82. Gellad WF, et al. Use of antipsychotics among older residents in VA nursing homes. Med Care. 2012;50:954–60.

83. Shah SM, Carey IM, Harris T, Dewilde S, Cook DG. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry. 2011;26:423–34.

84. Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gunwitz JH. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170:89–95.

85. van Asch IF, Nuyen J, Veerbeek MA, Frijters DH, Achterberg WP, Pot AM. The diagnosis of depression and use of antidepressants in nursing home residents with and without dementia. Int J Geriatr Psychiatry. 2013;28:312–8.

86. Kim H, Whall AL. Factors associated with psychotropic drug usage among nursing home residents with dementia. Nurs Res. 2006;55:252–8.

87. Diaz E, Kumar BN, Engedal K. Immigrant patients with dementia and memory impairment in primary health care in Norway: a national registry study. Dement Geriatr Cogn Disord. 2015;39:321–31.

88. Leoutsakos JM, et al. Effects of general medical health on Alzheimer’s progression: the cache county dementia progression study. Int Psychogeriatr. 2012;24:1561–70.